I know PSDV isn't talking, they just can't say. But, let's just read between the lines here. The Dr. Guo presentation was filled with Roche/Genentech drugs; Avastin, Lucentis and finally Herceptin. Sorry Regeneron's Eylea was mentioned, but not in a graph. Roche has a tech agreement with Forsight for sustained release. But, it was my theory all along that the best technology is going to win this battle. I don't see anything from Forsight Vision4 lately, and obviously Roche is researching all sustained release options.
Friday, Jan 13, 2012
Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery Lucentis
South San Francisco, Calif. -- January 13, 2012 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced it will make its first milestone payment to ForSight VISION4, Inc. as part of an exclusive license agreement to develop the company's investigational drug delivery device, designed to provide sustained delivery of Lucentis® (ranibizumab).
Genentech and Roche entered into an agreement with ForSight VISION4 in December 2010 for exclusive worldwide rights to the company's proprietary implantable ocular device in the development and commercialization of anti-VEGF-A targeted ophthalmic therapies. This first undisclosed milestone payment is based on Genentech's decision to submit an Investigational New Drug (IND) application for clinical testing of the device in combination with Lucentis. Currently, Lucentis, which is indicated for treatment of certain eye diseases, is recommended to be administered by monthly injections to the eye.
"This development reflects Genentech's commitment to ophthalmology and investigating new technologies that may potentially provide sustained delivery of Lucentis and reduce the frequency of injections," said Hal Barron, M.D., chief medical officer and head, Global Product Development. "The license agreement with ForSight VISION4 represents part of our ongoing strategy to support the retinal community by innovating and discovering new ways to help people with sight-threatening illnesses."
The agreement provides Genentech with the opportunity to apply the device to other select targets for treatment of ophthalmic diseases. Genentech is responsible for clinical development and commercialization and is currently collaborating with ForSight VISION4 in the manufacturing and engineering of the device. ForSight VISION4 is entitled to undisclosed milestone payments and royalties on potential future sales.